At ADA 2024, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.
With the launch of the Dextrometer in 1980, blood glucose self-monitoring became the standard of care for patients with diabetes.1 Since then, advancements in diabetes technologies have increased rapidly, much like the prevalence of the condition itself.
Today, a plethora of diabetes technologies are available to patients with diabetes, with innovations continuously rolling out. Just last year, the FDA cleared the first-ever do-it-yourself automated insulin delivery system.2 Even more recently, the agency approved 2 new OTC continuous glucose monitors (CGMs).3
Underscoring the progress in the industry, 4 abstracts presented at the American Diabetes Association 84th Scientific Sessions, held June 21 to 24 in Orlando, Florida, investigated the impact of various new diabetes technologies on managing the condition.
Click here for more of our coverage from ADA 2024.
READ MORE: Diabetes Resource Center
Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.
Teva Pharmaceuticals Launches Liraglutide Injection 1.8 mg, First Generic GLP-1 in the US
The Victoza generic is approved for use in adults and children aged 10 years and older.
Episode 6: High Risk: Diabetes and COVID-19
In this episode of Over the Counter, 2 experts on diabetes management and care discuss the effect COVID-19 is having on individuals with diabetes and the ways that the health care system is responding.
GLP-1s Improve Taste Sensitivity, Reduce Body Weight in Patients with Obesity
Two posters presented at ENDO 2024 assessed semaglutide’s impact on taste sensitivity and tirzepatide’s role in body weight reduction.
Increasing Prevalence of T1D Calls for Age-Specific Clinical Guidelines of Management
Clinical recommendations for the management of type 1 diabetes (T1D) in older adults are urgently needed as the global population ages and as improved diabetes care and management of complications have extended the life expectancy of the patient population.
FDA Approves Dapagliflozin to Treat Pediatric Patients with Type 2 Diabetes
The therapy from AstraZeneca is indicated to improve glycemic control in patients aged 10 years or older.
CGM, Wearable Device Data to Improve Mortality, Establish Lifestyle Changes
In a session presented at the 2024 Heart in Diabetes Conference, researchers discussed the abilities of continuous glucose monitoring (CGM) to capture lifestyle data and improve mortality rates.
Teva Pharmaceuticals Launches Liraglutide Injection 1.8 mg, First Generic GLP-1 in the US
The Victoza generic is approved for use in adults and children aged 10 years and older.
Episode 6: High Risk: Diabetes and COVID-19
In this episode of Over the Counter, 2 experts on diabetes management and care discuss the effect COVID-19 is having on individuals with diabetes and the ways that the health care system is responding.
GLP-1s Improve Taste Sensitivity, Reduce Body Weight in Patients with Obesity
Two posters presented at ENDO 2024 assessed semaglutide’s impact on taste sensitivity and tirzepatide’s role in body weight reduction.
Increasing Prevalence of T1D Calls for Age-Specific Clinical Guidelines of Management
Clinical recommendations for the management of type 1 diabetes (T1D) in older adults are urgently needed as the global population ages and as improved diabetes care and management of complications have extended the life expectancy of the patient population.
FDA Approves Dapagliflozin to Treat Pediatric Patients with Type 2 Diabetes
The therapy from AstraZeneca is indicated to improve glycemic control in patients aged 10 years or older.
CGM, Wearable Device Data to Improve Mortality, Establish Lifestyle Changes
In a session presented at the 2024 Heart in Diabetes Conference, researchers discussed the abilities of continuous glucose monitoring (CGM) to capture lifestyle data and improve mortality rates.
2 Commerce Drive
Cranbury, NJ 08512
609-716-7777
